Oncimmune

Oncimmune has developed the most advanced and comprehensive analytical platform for the discovery of Antibody and Autoantibody Biomarker Signatures. Their flagship product, ImmunoINSIGHTS, is a best-in-class biomarker discovery engine that provides access to the B cell repertoire. With one of the world's largest antigen libraries covering 9,000+ human antigens and multi-species variants, the platform profiles antibodies from various biologic samples in very low volume (50 µl). Developed and curated by immunologists and bioinformaticians, the platform offers high-content biological insights and analytics powered by proprietary machine learning algorithms. Oncimmune's technology uses Luminex xMAP — the world's most used multiplexing technology — and its mission is to improve understanding of the immune system to enable more effective, targeted, and safer treatments and better diagnosis. Oncimmune was originally a UK-based company and is now an Alden Scientific company, operating from Cambridge, MA.